RH
Therapeutic Areas
Biodesix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nodify XL2® | Lung Nodule Risk Assessment (Malignant vs. Benign) | Commercial |
| Nodify CDT® | Lung Nodule Risk Assessment (Malignant vs. Benign) | Commercial |
| GeneStrat® | Therapy Selection & Monitoring in Non-Small Cell Lung Cancer (NSCLC) | Commercial |
| VeriStrat® | Prognostic & Predictive Test for NSCLC Therapy | Commercial |
| IQLung™ | Integrated Diagnostic Report for NSCLC | Commercial |
| COVID-19 Severity Test | Predicting Disease Severity in Hospitalized COVID-19 Patients | Development |
Leadership Team at Biodesix
SH
Scott Hutton
Chief Executive Officer
GA
Gary A. Pestano
Chief Development Officer & Vice President of Laboratory Operations
DB
David Brunel
Chief Executive Officer (Previous)
RP
Ryan Parasch
Senior Vice President of Commercial
PO
Paul O’Donnell
Senior Vice President of Strategy & Corporate Development
KS
Katherine S. Zanotti
Chairperson of the Board of Directors
HM
Hugh M. Jones III
Director
SL
Stephen L. Hoffman
Director
AJ
Andrea J. Walsh
Director
HL
Heather L. Getz
Director